Under 10% of people that would benefit from obesity jabs like Wegovy are able to get them, states the WHO as it releases its inaugural recommendations on the medications.
Given over a billion individuals worldwide now classified as obese, it is advocating for broader and more equitable access to these injectable treatments.
According to forecasts, in excess of 2,000,000,000 will be obese by 2030 if no action is taken.
"The latest guidelines recognises that obesity is a lifelong illness that can be managed with holistic and lifelong care," stated the agency's head Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and logistical bottlenecks are significant obstacles to broad access to the treatments that can help people shift substantial body mass, explains the body.
Weight-Loss Drug Scarcity
Despite the present best projected case, the manufacturing of GLP-1 therapies would only suffice for approximately 100 million people – under 10% of those who need them, per the health organization.
The recommendation calls on countries and companies to widen access, by strategies such as licensing agreements.
A patent on semaglutide – the main component of a leading brand – is due to expire in a number of nations in 2026.
The Way Obesity Injections Work
These medications imitate a biological compound to reduce digestion speed, curb appetite and enhance feelings of fullness so people reduce food intake.
Individuals usually begin shedding pounds in the initial weeks of commencing the weekly injections.
Evidence indicates patients may see weight return after a year of halting the treatment, as their normal hunger return.
To be above a healthy weight raises your likelihood for experiencing health problems, like type 2 diabetes, cardiovascular issues, stroke, and certain cancers.
Excess weight affects people in every country and was responsible for over three and a half million deaths worldwide in 2024, according to the WHO.
